Ruthenium Pyrazole Complex for NSCLC Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, such as platinum-based drugs, face limitations due to toxicity and emerging drug resistance, necessitating the development of more targeted and less toxic anticancer agents.

Innovation Solution

The use of a neutral ruthenium (III)-pyrazole complex, specifically RuCl3(DMSO)(dmPyz)2, which is administered in proper dosages to target and treat certain types of cancer, including non-small cell lung cancer subtypes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If platinum-based drugs like Cisplatin are used to treat cancer, then cancer treatment effectiveness is improved, but toxicity and side effects increase

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidtoxicity and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the metal center from platinum to ruthenium, altering the chemical parameters of the anticancer agent. This substitution maintains therapeutic efficacy while reducing toxicity, as ruthenium complexes exhibit different biological properties and lower systemic side effects compared to platinum-based drugs

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention uses a composite ruthenium complex structure with specific ligands (bpy, dmpyz, DMSO) coordinated to the ruthenium center. This composite molecular structure enables targeted anticancer activity while minimizing harmful effects on healthy tissues through optimized ligand-metals interactions

Inventive Principle:

Principle #40Composite materials

2Reliability

If platinum-based drugs are used to treat cancer, then cancer cell killing activity is improved, but drug resistance develops

Engineering Contradiction:

Improvecancer cell killing activityVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

By changing the metal center from platinum to ruthenium and adjusting ligand parameters, the patent creates a chemically distinct anticancer agent that bypasses resistance mechanisms developed against platinum drugs, thereby maintaining effectiveness against resistant cancer cells

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If Ruthenium complexes are used to target cancerous tissue, then specificity to cancer cells is improved, but genotoxic activity increases

Engineering Contradiction:

Improvespecificity to cancerous tissueVSAvoidgenotoxic activity

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent employs ligands with specific local chemical properties (bpy, dmpyz, DMSO) that modify the ruthenium complex's interaction with biological molecules. These ligands create localized chemical environments that enhance cancer cell targeting while reducing non-specific genotoxic damage to healthy cells

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12303484B2Method of treating cancer

Publication Date: 2025.05.20 UNIVERSITY OF LOUISIANA AT LAFAYETTE

AI summary

Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl3(DMSO)(dmPyz)2.